21st Annual Cancer Progress Conference
March 16-17, 2010
Program

Program Moderators:
Jeremy P. Goldberg, JPG Healthcare LLC
Mark Simon, President, Williver Group LLC

Keynote Presentation: Cancer Stem Cells and the Development of High-Grade Malignancy
Robert A. Weinberg, PhD, Member, Whitehead Institute, Professor of Biology, MIT

Keynote Presentation: Taking the Cellulite Out of Cancer
Daniel D. Von Hoff, MD, Physician-in-Chief, Director, Translational Research, TGen, Clinical Professor of Medicine, University of Arizona

Panel Discussion: Steps on the Promise of Targeted Therapies
Co-Moderators: Markus Goebel, MD, PhD, Managing Director, Novartis Venture Fund
Prof. Michel Aguet, MD, Director, Swiss Institute for Experimental Cancer Research (ISREC)
Neal Rosen, MD, PhD, Enid A. Haupt Chair in Medical Oncology, Memorial Sloan-Kettering Cancer Center
TORC1/2 - Christian Rommel, PhD, CSO, Intellikine
PI3K Delta Inhibitor - Albert S. Yu, MD, VP, Medical Affairs & CMO, Calistoga Pharmaceuticals
AKT Inhibitor - Li Yan, MD, PhD, Director, Clinical Oncology, Merck
PMT - New enzyme class - Robert Copeland, PhD, EVP & CSO, Epizyme
BRAF Inhibitor for Melanoma - K. Peter Hirth, PhD, CEO, Plexxikon
ALK Inhibitors - Martine George, MD, MSc, VP, Medical Affairs, Pfizer Oncology

Panel Discussion: Patient Stratification: Impact on Drug Development and Commercialization
Moderator: Richard Gaynor, MD, VP, Cancer Research & Clinical Investigation, Eli Lilly
Joseph R. Nevins, PhD, Barbara Levine Professor for Breast Cancer, Director, IGSP Center for Applied Genomics and Technology, Duke University Medical Center
David Schenkein, MD, PhD, CEO, Agios Pharmaceuticals
Steven J. Heller, Global Marketing Leader, Oncology GSM, Worldwide Strategic Marketing, Johnson & Johnson  
Matthew Meyerson, MD, PhD, Professor of Pathology, Harvard Medical School/Broad Institute

Novel Antiandrogens for Prostate Cancer
Charles Sawyers, MD, Chairman, MemorialSloan-KetteringCancerCenterHuman Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center

Special Presentation: New Institutional and Technical Approaches to Tackle the Cancer Problem
Robert G. Urban, PhD, Executive Director, David H. Koch Institute for Integrative Cancer Research, MIT

Merck-AstraZeneca-New Paradigm in Drug Development
Pearl Huang, PhD, Vice President, Franchise Integrator, Oncology, Merck  

The Challenge of Targeting EGFR: Lessons Learnt and Future Directions With Gefitinib
Alison A. Armour, MD, Iressa Medical Science Director, AstraZeneca ,UK

Panel Discussion: Genomic Strategies for Rational Combinations of Targeted Therapies
Moderator: David C. Heimbrook, PhD, VP Oncology Global Therapeutic Area, Roche
David Solit, MD, Elizabeth and Felix Rohatyn Chair, Memorial Sloan-Kettering Cancer Center
Jeffrey Engelman MD, PhD, Assistant Professor in Medicine at Harvard Medical School, Director, Thoracic Oncology, Massachusetts General Hospital Cancer Center
Brian Leyland-Jones, MD, PhD, Winship Cancer Institute, Emory University
Colin Hill, CEO, Gene Network Sciences
Stuart Lutzker, MD, PhD, VP BioOncology Exploratory Clinical Development, Genentech

Panel Discussion: Do Novel Therapeutics Need Companion Diagnostics?
Panel Moderator: Steven D. Averbuch, MD, VP Oncology Transition Strategy & Development and Head, Pharmacodiagnostics Global Clinical Research, Bristol-Myers Squibb
Brian Leyland-Jones, MD, PhD, Winship Cancer Institute, Emory University
Daniel J. Sargent, PhD, Professor of Oncology, Professor of Biostatistics, Mayo Clinic
Neil Gunn, MSc, PhD, Vice President Global Business, Roche Molecular Systems
Mark Ratain, MD, Leon O. Jacobson Professor of Medicine, Chairman, Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago
Randy Scott, Executive Chairman, Genomic Health
Elizabeth Mansfield, PhD, Senior Genomics Advisor, Office of FDA Chief Scientist, FDA 
Felix W. Frueh, PhD, Vice President, R&D - Personalized Medicine, Medco Health Solutions, Inc.
Bruce Quinn, MD, Senior Health Policy Specialist, Foley Hoag, LLP

Panel Discussion: Adaptive Trial Design
Moderator: Eric Rubin, MD, VP Oncology Clinical Research, Merck
Mark Ratain, MD, Leon O. Jacobson Professor of Medicine, Chairman, Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago
Donald Berry, PhD, Head, Division of Quantitative Sciences and Chairman, Department of Biostatistics and Frank T. McGraw Memorial Chair of Cancer Research, MD Anderson Cancer Center
Roy S. Herbst, MD, PhD, Professor of Medicine, Department of Thoracic Head and Neck Cancer, Division of Cancer Medicine, MD Anderson Cancer Center
Sue-Jane Wang, PhD, Associate Director for Adaptive Design and Pharmacogenomics, Office of Biostatistics, OTS/CDER/FDA (invited)

New Imaging Strategies Beyond RECIST
David Geho, MD, PhD, Clinical Project Leader, General Electric Corporation
Lawrence H. Schwartz, MD, James Picker Professor & Chairman, Department of Radiology, New York Columbia-Presbyterian Medical Center
Nola Hylton, PhD, Professor of Radiology, Director, MRI Research Program, UCSF
Wendy Hayes, DO, Imaging Director, Discovery Medicine and Clinical Pharmacology, Bristol-Myers Squibb
Gary Kelloff, MD, Special Advisor, Division of Cancer Treatment & Diagnosis, NCI, NIH

Market Access Under Healthcare Reform
Lee Blansett, Senior Vice President, Kantar Health

Registration Form       Preliminary Agenda        Discussion       Sponsors       Communitech